Profile: Aldagen, Inc. is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We also conduct or support Phase 1 or Phase 1/2 clinical trials of three product candidates ALD-151 to improve cord blood transplants used for the treatment of leukemia, ALD-301 to treat critical limb ischemia, and ALD-201 to treat ischemic heart failure. We develop ALD-151 stem cells to improve cord blood transplants used to treat leukemias. Our ALD-201 is the population of ALDHbr stem cells produced to sort a specified quantity of bone marrow collected from the patient receiving the therapy, and it is being developed for the treatment of ischemic heart failure. Our Aldefluor is a reagent system for use in research activities to identify and isolate stem cells & progenitor cells based on ALDH activity.